Aptamer Group plc, a developer of next-generation synthetic binders, has announced progress in its enzyme modulation projects and a separate collaboration with a top five pharmaceutical company, marking key advancements in licensing and development.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Aptamer Group plc, a developer of next-generation synthetic binders, has announced progress in its enzyme modulation projects and a separate collaboration with a top five pharmaceutical company, marking key advancements in licensing and development.
